Artificial pancreas improves control of glucose levels for diabetics
12 March 2013
The trial of the MD-Logic artificial pancreas in controlling
glucose levels during the night has shown it results in
significantly fewer events of hypoglycemia and shortened the time
patients spent with glucose levels below the normal range as
compared to the use of pumps and sensors (control group).
Furthermore, the glucose concentration was maintained within the
narrow near-normal range for significantly more time with the
MD-Logic artificial pancreas as compared to the control without the
need of patients' intervention.
The clinical trial was performed in three academic centres: Jesse
Z and Sara Lea Shafer Institute for Endocrinology and Diabetes,
National Center for Childhood diabetes at the Schneider Children's
Medical Center of Israel in Petah Tikva, Israel headed by Prof.
Moshe Phillip, the Department of Pediatric Endocrinology, Diabetes
and Metabolism headed by Prof. Tadej Battelino at the University
Children's Hospital in Ljubljana, Slovenia, and the Department of
Pediatric Endocrinology and Diabetes headed by Prof. Thomas Danne &
Prof. Olga Kordonouri at the Kinderkrankenhaus AUF DER BULT in
Together, the three centres developed the DREAM (Diabetes
Wireless Artificial Pancreas Consortium) project aiming at clinical
development of the MD-Logic artificial pancreas for routine use by
the people with insulin dependent diabetes.
"Night time is a sensitive period of the day during which people
with diabetes are not able to consciously control their blood
glucose levels and are therefore exposed to extreme fluctuations.
Using the MD-Logic artificial pancreas system might change the
patients' lives. The results of this study are crucial for further
clinical development of a device that could be routinely used as a "Glucositter"
at home", says the principal investigator Prof. Moshe Phillip of the
Schneider Children's Medical Center of Israel ".
Moreover, "the use of the MD-Logic artificial pancreas during the
night time may, for the first time, bring some long desired relieve
to patients and parents of people with insulin dependent diabetes"
adds Prof. Tadej Battelino. "Clinical development of the MD-Logic
artificial pancreas system will bring our patients the freedom of a
more relaxed lifestyle at no cost to their glucose control," says
Prof. Thomas Danne.
Millions of children, adolescents and adults suffer from insulin
dependent diabetes which necessitates tight control of blood glucose
concentration for preventing acute and long-term complications.
Meticulous glycemic control is demanding and requires detailed
planning of the diet, physical activity and insulin dosing.
The MD-Logic artificial pancreas was developed by the Diabetes
Technology Center at the National Center for Childhood Diabetes at
Schneider Children's Medical Center of Israel to assist patients
with diabetes in achieving the goal of good glycemic control without
the burden it usually entails.
The multidisciplinary team of doctors, engineers, nurses and
dieticians developed the MD-Logic artificial pancreas algorithm
which controls routinely available insulin pumps based on the
measurements provided by approved subcutaneous continuous glucose
The MD-Logic artificial pancreas algorithm processes the
information received from the individual patient, learns her or his
specific requirements and based on the glucose concentration
commands the minute-to-minute amount of insulin injected into the